Reimbursed Care Access in Virgin Islands (U.S.)

Currently classified as a strictly controlled hallucinogenic substance under the U.S. Virgin Islands controlled substances schedules, explicitly listing psilocybin and psilocin among hallucinogens prohibited outside authorized channels. Local statute lists psilocybin/psilocin as controlled hallucinogenic substances. # Federally, psilocybin is a Schedule I substance under the Controlled Substances Act and associated DEA scheduling regulations, making non‑research medical use illegal outside of approved clinical trials. # Currently no routine public or private insurance reimbursement pathway exists in USVI for psilocybin therapy; access is limited to FDA‑regulated clinical trials or research programs.

MDMA is a Schedule I controlled substance under U.S. federal law and is treated similarly under USVI controlled‑substance law (no authorized medical use outside approved research). Possession, distribution, or medical administration outside of an FDA‑approved/DEA‑authorized clinical trial would be unlawful. # There is no standard reimbursement pathway in USVI for MDMA‑assisted therapy; any access would occur only within approved clinical research protocols.

Esketamine (SPRAVATO®) is approved by the U.S. Food and Drug Administration for certain depressive indications and is a Schedule III controlled substance; it is dispensed only through certified treatment centers under a REMS program. The FDA approval and REMS requirements (facility certification, observed dosing and post‑dose monitoring) apply across U.S. jurisdictions including U.S. territories. # # Practical reimbursement in the U.S. Virgin Islands is variable: payers (commercial insurers, Medicaid/territorial plans) frequently require prior authorization and impose utilization controls; Medicare/Medicaid policy for Spravato and specialty drug coverage is determined at the contractor/plan level and can differ for territories, so patients in USVI should expect case‑by‑case coverage decisions and prior authorization requirements. For programmatic and safety reasons Spravato administration must occur in certified clinics and is usually billed through medical benefit channels when covered. (Note: Spravato is the only FDA‑approved esketamine product for TRD/MDD indications; racemic ketamine is not FDA‑approved for psychiatric indications.) #

Ketamine (racemate) is an FDA‑approved anesthetic but is NOT FDA‑approved for psychiatric indications; it is commonly used off‑label in private infusion clinics for treatment‑resistant depression and other psychiatric conditions. Off‑label ketamine infusion therapy is typically delivered in private clinics and is usually paid out‑of‑pocket because routine public and private insurance reimbursement is uncommon; coverage decisions vary by insurer and most payers require strong justification or deny coverage because the indication is off‑label. The FDA has issued advisories clarifying ketamine is not approved for psychiatric disorders and warning about safety issues with compounded or unsupervised products. # In the USVI context, clinical availability would rely on licensed physicians/clinics; reimbursement is case‑by‑case and generally limited — patients should expect to coordinate with private insurers or self‑pay. Where reimbursement exists, it is typically subject to prior authorization and strict medical necessity documentation.

Currently classified as a strictly controlled substance under USVI law (DMT and related tryptamines are explicitly listed among controlled hallucinogens) and at the federal level as Schedule I; no authorized medical use outside approved clinical research. Access in USVI is therefore limited to DEA/FDA‑authorized research protocols. # #

Currently classified as a strictly controlled substance under national and territorial scheduling (tryptamine derivatives including 5‑MeO‑DMT are covered by federal/territorial lists) with no authorized medical use outside approved clinical research. Access in the USVI is limited to authorized research. # #

Currently classified as a strictly controlled substance in the USVI code listing hallucinogens (ibogaine appears in territorial schedules) and is treated as a Schedule I substance under U.S. federal scheduling frameworks with no authorized medical use outside approved clinical research. There is no routine reimbursed medical access in USVI; access is restricted to approved clinical trials. # #

Because ayahuasca preparations contain DMT (a Schedule I substance) and USVI law lists DMT/related hallucinogens among controlled substances, ayahuasca is effectively controlled and not authorized for general medical use outside approved research or narrow religious exceptions that require federal/territorial exemptions. Standardized boilerplate: "Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research." # #

Mescaline is explicitly referenced in USVI territorial hallucinogen lists and is Schedule I at the federal level; possession or medical use outside authorized research is prohibited. Note that U.S. federal law provides narrow, strictly regulated religious exemptions for use of peyote in bona fide Native American religious ceremonies under specific federal provisions — those narrow exemptions do not create a general medical or reimbursable pathway in USVI. Standardized boilerplate: "Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research." # #

Many 2C family compounds and related substituted phenethylamines/amphetamine analogues are controlled under territorial law (the USVI schedule lists numerous substituted amphetamines/hallucinogens) and are treated as Schedule I/controlled substances at the federal level or as prosecutable analogues under the Federal Analogue Act if structurally similar and intended for human consumption. Standardized boilerplate: "Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research." (Also note legal risk from the Federal Analogue Act for unlisted but substantially similar compounds.) # #